Market LIVE
Published markets; coverage varies by country
Product profile · United States

XIGDUO XR

 ·  Patent Litigation & Settlement History ↓

IngredientDAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Application typeNDA
Application205649
Product004
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
Strength10MG;1GM
Approval date2014-10-29
Marketing statusPrescription
Status event—
ApplicantASTRAZENECA AB
Product source

Current GenericRadar decision

Year2026
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2026-04-06
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2026-04-06
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
65151172025-10-04DS/DP/U U-493———
———
65151172026-04-04— ————
—2026-04-04—
85016982027-06-20DP/U U-493———
———
85016982027-12-20— ————
—2027-12-20—
79195982029-12-16DS ————
———
86859342030-05-26U U-1522———
———
79195982030-06-16— ————
—2030-06-16—
96160282030-11-12DP ————
———
86859342030-11-26— ————
—2030-11-26—
96160282031-05-12— ————
—2031-05-12—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NPP—2027-06-12————Source
PED—2027-12-12————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211466 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—MICRO LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211479 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211489 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211491 / 003FINAL_APPROVAL · FINAL_APPROVED2026-04-06—SUN PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211536 / 003FINAL_APPROVAL · FINAL_APPROVED2026-04-06—CIPLA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211559 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211563 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211579 / 004FINAL_APPROVAL · FINAL_APPROVED2026-04-06—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211583 / 005FINAL_APPROVAL · FINAL_APPROVED2026-04-06—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 9 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211466 / 004MICRO LABS LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211479 / 004MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211489 / 004AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211491 / 003SUN PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211536 / 003CIPLA LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211559 / 004MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211563 / 004ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211579 / 004LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211583 / 005TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2026-04-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2026-04-06TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.